News >

CRM1 Emerges as a Potential Target in Osteosarcoma in Novel Drug Discovery Model

Caroline Seymour
Published: Tuesday, Feb 25, 2020

Alexander Leandros Lazarides, MD, a resident at Duke University Medical Center

Alexander Leandros Lazarides, MD

In a high-throughput screen, investigators demonstrated similar in vitro and in vivo antitumor activity with CRM1 inhibitors in dog and human osteosarcoma–derived cell lines and xenografts, respectively, validating a comparative cross-species precision medicine pipeline that has the potential to enhance drug discovery in a difficult-to-treat disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication